Prognostic biomarker CPEB3 and its associations with immune infiltration in clear cell renal cell carcinoma
- Authors:
- Hualan Hong
- Xi Shi
- Wenyong Ou
- Pengju Ou
-
Affiliations: Department of Medical Oncology, Cancer Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350000, P.R. China, Department of Surgery 1, Longyan People Hospital, Longyan, Fujian 364000, P.R. China - Published online on: February 19, 2024 https://doi.org/10.3892/br.2024.1751
- Article Number: 63
-
Copyright: © Hong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML and Cheville JC: Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 183:1309–1315. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, et al: Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. Lancet Oncol. 23:292–303. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, et al: Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 384:1289–1300. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, et al: Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 384:829–841. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, et al: Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 21:1563–1573. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al: Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 378:1277–1290. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, et al: Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med. 385:683–694. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, et al: Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. 39:649–661.e5. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, Zhang Y, Zhao W, Zhou F, Li W, et al: Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 12(2540)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ma L, Hernandez MO, Zhao Y, Mehta M, Tran B, Kelly M, Rae Z, Hernandez JM, Davis JL, Martin SP, et al: Tumor cell biodiversity drives microenvironmental reprogramming in liver cancer. Cancer Cell. 36:418–430.e6. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Barkley D, Moncada R, Pour M, Liberman DA, Dryg I, Werba G, Wang W, Baron M, Rao A, Xia B, et al: Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nat Genet. 54:1192–1201. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Nakamura K and Smyth MJ: Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 17:1–12. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, Kamada T, Irie T, Okumura G, Kono H, et al: Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 40:201–218.e9. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Naser R, Fakhoury I, El-Fouani A, Abi-Habib R and El-Sibai M: Role of the tumor microenvironment in cancer hallmarks and targeted therapy (review). Int J Oncol. 62(23)2023.PubMed/NCBI View Article : Google Scholar | |
|
Josefowicz SZ, Lu LF and Rudensky AY: Regulatory T cells: Mechanisms of differentiation and function. Annu Rev Immunol. 30:531–564. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Khattri R, Cox T, Yasayko SA and Ramsdell F: Pillars article: An essential role for scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 2003.4:337-342. J Immunol. 198:993–998. 2017.PubMed/NCBI | |
|
Hori S, Nomura T and Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057–1061. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 4:330–336. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 155:1151–1164. 1995.PubMed/NCBI | |
|
Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, Doi T, Wada H, Nishikawa H and Shitara K: Targeting VEGFR2 with Ramucirumab strongly impacts effector/activated regulatory T cells and CD8+ T cells in the tumor microenvironment. J Immunother Cancer. 6(106)2018.PubMed/NCBI View Article : Google Scholar | |
|
Togashi Y and Nishikawa H: Regulatory T cells: Molecular and cellular basis for immunoregulation. Curr Top Microbiol Immunol. 410:3–27. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, et al: Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22:679–684. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Mendez R, Barnard D and Richter JD: Differential mRNA translation and meiotic progression require Cdc2-mediated CPEB destruction. EMBO J. 21:1833–1844. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Chen J, Li L, Liu TY, Fu HF, Lai YH, Lei X, Xu JF, Yu JS, Xia YJ, Zhang TH, et al: CPEB3 suppresses gastric cancer progression by inhibiting ADAR1-mediated RNA editing via localizing ADAR1 mRNA to P bodies. Oncogene. 41:4591–4605. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Cheng J, Ma H, Yan M, Zhang Z and Xing W: Circ_0007624 suppresses the development of esophageal squamous cell carcinoma via targeting miR-224-5p/CPEB3 to inactivate the EGFR/PI3K/AKT signaling. Cell Signal. 99(110448)2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhong Q, Fang Y, Lai Q, Wang S, He C, Li A, Liu S and Yan Q: CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling. J Exp Clin Cancer Res. 39(132)2020.PubMed/NCBI View Article : Google Scholar | |
|
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al: Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 38:675–678. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Vivian J, Rao AA, Nothaft FA, Ketchum C, Armstrong J, Novak A, Pfeil J, Narkizian J, Deran AD, Musselman-Brown A, et al: Toil enables reproducible, open source, big biomedical data analyses. Nat Biotechnol. 35:314–316. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Cancer Genome Atlas Research Network. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM: The cancer genome atlas pan-cancer analysis project. Nat Genet. 45:1113–1120. 2013.PubMed/NCBI View Article : Google Scholar | |
|
GTEx Consortium: Human genomics. The genotype-tissue expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science. 348:648–660. 2015.PubMed/NCBI View Article : Google Scholar | |
|
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2019. | |
|
Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, et al: UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 25:18–27. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15(550)2014.PubMed/NCBI View Article : Google Scholar | |
|
Villanueva RAM and Chen ZJ: ggplot2: Elegant graphics for data analysis (2nd ed.). Meas: Inter Res Perspect. 17:160–167. 2019. | |
|
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al: Gene ontology: Tool for the unification of biology. The gene ontology consortium. Nat Genet. 25:25–29. 2000.PubMed/NCBI View Article : Google Scholar | |
|
Gene Ontology Consortium. Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, Feuermann M, Gaudet P, Harris NL, et al: The gene ontology knowledgebase in 2023. Genetics. 224(iyad031)2023.PubMed/NCBI View Article : Google Scholar | |
|
Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Walter W, Sánchez-Cabo F and Ricote M: GOplot: An R package for visually combining expression data with functional analysis. Bioinformatics. 31:2912–2914. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP and Tamayo P: The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1:417–425. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al: Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 39:782–795. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Hänzelmann S, Castelo R and Guinney J: GSVA: Gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 14(7)2013.PubMed/NCBI View Article : Google Scholar | |
|
Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H and Trajanoski Z: Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18:248–262. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 48 (W1):W509–W514. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Therneau TM: A package for survival analysis in R. https://CRAN.R-project.org/package=survival. | |
|
Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC and Müller M: pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 12(77)2011.PubMed/NCBI View Article : Google Scholar | |
|
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC (eds), et al: AJCC cancer staging manual. 8th edition. New York: Springer, 2017. | |
|
Pablo C, Marcela G, Lía EA and María IA: Correlation between MVD and two prognostic factors: Fuhrman grade and tumoral size, in clear cell renal cell carcinoma. J Cancer Sci Ther. 4:313–316. 2012. | |
|
Kim SP, Alt AL, Weight CJ, Costello BA, Cheville JC, Lohse C and Leibovich BC: Independent validation of the 2010 American joint committee on cancer TNM classification for renal cell carcinoma: Results from a large, single institution cohort. J Urol. 185:2035–2039. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, et al: Prognostic impact of tumor size on pT2 renal cell carcinoma: An international multicenter experience. J Urol. 178:35–40. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Ged Y, Markowski MC, Singla N and Rowe SP: The shifting treatment paradigm of metastatic renal cell carcinoma. Nat Rev Urol. 19:631–632. 2022.PubMed/NCBI View Article : Google Scholar | |
|
No authors listed. New treatments emerge for RCC. Cancer Discov. 11(OF10)2021.PubMed/NCBI View Article : Google Scholar | |
|
Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, Krishnan I, Maroni G, Meyerovitz CV, Kerwin CM, et al: Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 50:1317–1334.e10. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, et al: Neoantigen-directed immune escape in lung cancer evolution. Nature. 567:479–485. 2019.PubMed/NCBI View Article : Google Scholar | |
|
McGranahan N and Swanton C: Cancer evolution constrained by the immune microenvironment. Cell. 170:825–827. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Vesely MD, Kershaw MH, Schreiber RD and Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 29:235–271. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ and Schreiber RD: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903–907. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al: Long-Term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J Clin Oncol. 40:127–137. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, et al: Safety and efficacy of pembrolizumab in combination with acalabrutinib in advanced head and neck squamous cell carcinoma: Phase 2 proof-of-concept study. Clin Cancer Res. 28:903–914. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Slomski A: Pembrolizumab boosts breast and cervical cancer survival. JAMA. 326(2001)2021.PubMed/NCBI View Article : Google Scholar | |
|
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 373:123–135. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ugel S, Canè S, De Sanctis F and Bronte V: Monocytes in the tumor microenvironment. Annu Rev Pathol. 16:93–122. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Li C, Teixeira AF, Zhu HJ and Ten Dijke P: Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 20(154)2021.PubMed/NCBI View Article : Google Scholar | |
|
Cheng HS, Lee JXT, Wahli W and Tan NS: Exploiting vulnerabilities of cancer by targeting nuclear receptors of stromal cells in tumor microenvironment. Mol Cancer. 18(51)2019.PubMed/NCBI View Article : Google Scholar | |
|
Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, Holland EC, Sutton JC and Joyce JA: The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 352(aad3018)2016.PubMed/NCBI View Article : Google Scholar | |
|
De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et al: Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 539:443–447. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med. 19:1423–1437. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Coussens LM, Zitvogel L and Palucka AK: Neutralizing tumor-promoting chronic inflammation: A magic bullet? Science. 339:286–291. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X and Shi S: Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol Cancer. 20(131)2021.PubMed/NCBI View Article : Google Scholar | |
|
Erez N, Truitt M, Olson P, Arron ST and Hanahan D: Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell. 17:135–147. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Gajewski TF, Schreiber H and Fu YX: Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 14:1014–1022. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Wade RJ and Burdick JA: Engineering ECM signals into biomaterials. Mater Today. 15:454–459. 2012. | |
|
Baumeister SH, Freeman GJ, Dranoff G and Sharpe AH: Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 34:539–573. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Masugi Y, Nishihara R, Hamada T, Song M, da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, et al: Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer. Cancer Immunol Res. 5:1046–1055. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Wolf Y, Anderson AC and Kuchroo VK: TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 20:173–185. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Anderson AC, Joller N and Kuchroo VK: Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 44:989–1004. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Reschke R and Gajewski TF: CXCL9 and CXCL10 bring the heat to tumors. Sci Immunol. 7(eabq6509)2022.PubMed/NCBI View Article : Google Scholar | |
|
Duhen R, Fesneau O, Samson KA, Frye AK, Beymer M, Rajamanickam V, Ross D, Tran E, Bernard B, Weinberg AD and Duhen T: PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors. J Clin Invest. 132(e156821)2022.PubMed/NCBI View Article : Google Scholar | |
|
Yan C and Richmond A: Hiding in the dark: Pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy. Mol Cancer. 20(146)2021.PubMed/NCBI View Article : Google Scholar | |
|
Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T and Okazaki T: Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 364:558–566. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, et al: CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 8:1156–1175. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu Y, Wang L, Predina J, Han R, Beier UH, Wang LC, Kapoor V, Bhatti TR, Akimova T, Singhal S, et al: Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity. Nat Med. 19:1173–1177. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Grebinoski S, Zhang Q, Cillo AR, Manne S, Xiao H, Brunazzi EA, Tabib T, Cardello C, Lian CG, Murphy GF, et al: Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 23:868–877. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, Sopper S, Rieder D, Krogsdam A, Gamerith G, et al: Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun. 9(1538)2018.PubMed/NCBI View Article : Google Scholar |
